Characterization of the cytotoxic properties of the benzimidazole fungicides, benomyl and carbendazim, in human tumour cell lines and primary cultures of patient tumour cells

Anti-Cancer Drugs

Volumn 21, Issue 1, 2010, Pages 33-42

  Laryea, Daniel ^a   Gullbo, Joachim ^a   Isaksson, Anders ^a   Larsson, Rolf ^a   Nygren, Peter ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Benomyl; Carbendazim; Cross resistance; Cytotoxic drug; Gene expression; Tumour cell

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMSACRINE; ANTHRAMYCIN; ARSENIC TRIOXIDE; BENOMYL; BORTEZOMIB; CARBENDAZIM; CARBOPLATIN; CISPLATIN; COLCHICINE; CRYPTOLEPINE; CURCUMIN; DISULFIRAM; FENBENDAZOLE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; LACTACYSTIN; MEBENDAZOLE; MELPHALAN; MERCAPTOPURINE; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PODOPHYLLOTOXIN; RAPAMYCIN; ROTENONE; TUBULIN; UNINDEXED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS RESISTANCE; DNA MICROARRAY; DRUG CYTOTOXICITY; DRUG STRUCTURE; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; BENOMYL; BENZIMIDAZOLES; CARBAMATES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR STRUCTURE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR CELLS, CULTURED;

EID: 74349106449     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328330e74e     Document Type: Article

References (16)

1. Monico-Pifarre A, Xirau-Vayreda M. Study of carbendazim residue accumulation on greenhouse and field-grown strawberries, after successive treatments with benomyl. J Assoc Off Anal Chem 1990; 73:553-556.
2. Britten CD, Delioukina M, Boulos L, Reiswig L, Gicanov N, Rizzo J, et al. A phase I and pharmacokinetic (PK) study of FB642 administered orally on daily schedule to patients with advanced solid tumors. 2001 ASCO Annual Meeting 2001.
3. Hao D, Rowinsky E, Rizzo J, Rosen L, Felton S, Smetzer L, et al. A phase I and pharmacokinetic (PK) study of FB642 administered orally on a weekly schedule to patients (Pts) with advanced solid tumors. 2000 ASCO Annual Meeting 19: 2000 (Abstract 818).
4. Hellman B, Laryea D. Inhibitory action of benzimidazole fungicides on the in vivo incorporation of [3H]thymidine in various organs of the mouse. Food Chem Toxicol 1990; 28:701-706.
5. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 1994; 54:163-170. (Pubitemid 24256464)
6. Larsson R, Nygren P. Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. Int J Cancer 1990; 46:67-72.
7. Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, et al. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer 2005; 93:483-492.
8. Dhar S, Nygren P, Csoka K, Botling J, Nilsson K, Larsson R. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br J Cancer 1996; 74:888-896.
9. Winder BS, Strandgaard CS, Miller MG. The role of GTP binding and microtubule-associated proteins in the inhibition of microtubule assembly by carbendazim. Toxicol Sci 2001; 59:138-146.
10. Nygren P, Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med 2003; 253:46-75.
11. Rehnberg GL, Cooper RL, Goldman JM, Gray LE, Hein JF, McElroy WK. Serum and testicular testosterone and androgen binding protein profiles following subchronic treatment with carbendazim. Toxicol Appl Pharmacol 1989; 101:55-61.
12. Kroes RA, Abravaya K, Seidenfeld J, Morimoto RI. Selective activation of human heat shock gene transcription by nitrosourea antitumor drugs mediated by isocyanate-induced damage and activation of heat shock transcription factor. Proc Natl Acad Sci U S A 1991; 88:4825-4829.
13. Parker BS, Cutts SM, Nudelman A, Rephaeli A, Phillips DR, Sukumar S. Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells. Cancer Biol Ther 2003; 2:259-263.
14. Manku S, Allan M, Nguyen N, Ajamian A, Rodrigue J, Therrien E, et al. Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors. Bioorg Med Chem Lett 2009; 19:1866-1870.
15. Fryknas M, Dhar S, Oberg F, Rickardson L, Rydaker M, Goransson H, et al. STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int J Cancer 2007; 120:189-195.
16. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313:1929-1935.